[Disclosure] Celltrion (068270) Secures Final FDA Approval for Prolia & Xgeva Biosimilars ‘Stoboclo’ & ‘Osenvelt’

Source: Financial Supervisory Service Dart System / 2025-03-04

Disclosure Type: Key Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion’s ‘Stoboclo’ (Prolia biosimilar) and ‘Osenvelt’ (Xgeva biosimilar) have obtained final marketing authorization from the U.S. Food and Drug Administration (FDA) for all indications of the reference products in the United States.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Approved Products & Active Ingredient:
  • Stoboclo (CT-P41, biosimilar to Prolia, active ingredient: denosumab)
  • Osenvelt (CT-P41, biosimilar to Xgeva, active ingredient: denosumab)
• Target Indications:
  • Stoboclo: Treatment of postmenopausal women with osteoporosis at high risk for fracture, treatment to increase bone mass in men with osteoporosis at high risk for fracture, treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
  • Osenvelt: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
• Timeline of Application & Approval:
  • Application Date: November 30, 2023 (Local Time)
  • Approval Date: February 28, 2025 (Local Time)
• Approval Authority: U.S. Food and Drug Administration (FDA)
• Operational Plan & Expected Effect: Celltrion plans to distribute and sell both Stoboclo and Osenvelt (CT-P41) across the United States through its established U.S. subsidiary. Obtaining approval for all indications authorized for the reference products is expected to broaden therapeutic options.

📈 2. [Expert Perspective: What This Means for Investors]

• Securing Official Marketing Rights in the US: Following a review process of approximately one year and three months (applied on November 30, 2023, approved on February 28, 2025), Celltrion has cleared the FDA regulatory process. This grants the complete legal and administrative framework necessary to market both biosimilars derived from the CT-P41 project in the United States.
• Full Indication Matching: Stoboclo and Osenvelt have successfully secured approval for the complete spectrum of target disease indications of Prolia and Xgeva. This ensures that the clinical profile of the biosimilars completely aligns with the reference drugs for prescribing practices.
• Direct Local Distribution Plan: According to the business plan specified in the regulatory filing, Celltrion intends to execute sales across the United States via its local subsidiary, establishing a direct channel to supply the market.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has obtained final marketing authorization from the U.S. FDA for its Prolia and Xgeva biosimilars, ‘Stoboclo’ and ‘Osenvelt (CT-P41)’. Completing the rigorous administrative process since the initial submission in November 2023 allows the company to transition into the commercialization phase in the U.S. market.

The immediate check point for investors moving forward is the actual commercial launch date and the progress of the initial logistics through Celltrion’s U.S. subsidiary. Tracking the timeline from receiving official regulatory approval to the practical deployment of products to clinics and pharmacies is essential for understanding the operational milestones.

Rather than formulating speculative assumptions about future commercial results, investors are advised to objectively follow upcoming audited financial statements and quarterly corporate disclosures to verify the actual sales performance of these newly approved products in the United States.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.